MKDWELL Tech Board Approves 30-for-1 Share Combination
MKDWELL Tech Board of Directors has approved a share combination on its ordinary shares and the Class A Preferred Shares on a thirty-to-one basis. The Company will file an amended and restated memorandum and articles of association with the BVI Registry of Corporate Affairs to effect the Share Combination. The Share Combination will take effect at 9:00 a.m., Eastern Time, on January 26. The ordinary shares will continue to trade on The Nasdaq Capital Market under the existing symbol "MKDW" and will begin trading on a split-adjusted basis when the market opens on January 26. The new CUSIP number for the ordinary share following the Share Combination will be G6209W124. At the Effective Time, every 30 shares of the Company's issued ordinary shares will be automatically reclassified and combined into 1 ordinary share with no par value. As a result of the Share Combination, the number of issued ordinary shares will reduce from 141,039,933 shares to approximately 4,701,332 shares, and the number of ordinary shares outstanding will reduce from 106,459,933 to approximately 3,548,665 shares. No fractional shares will be issued in connection with the Share Combination and fractional amounts will be rounded up to the nearest whole number at the participant level. The Share Combination is a proactive measure as part of the Company's strategic plan to regain compliance with Nasdaq's continued listing requirements, while also strengthening the Company's long-term capital structure.
Get Free Real-Time Notifications for Any Stock
Analyst Views on MKDW
About MKDW
About the author
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
MKDWELL Tech Inc. Announces $7 Million Share Repurchase of 34.58 Million Shares
- Repurchase Plan: MKDWELL Tech Inc. has announced a stock repurchase agreement with certain shareholders to buy back 34.58 million ordinary shares at $0.203 per share, totaling approximately $7 million, aimed at enhancing shareholder value and reflecting confidence in the company's long-term growth potential.
- Market Response: The repurchase price is based on the average closing price over the twelve trading days preceding December 16, 2025, excluding the highest and lowest prices, indicating the company's emphasis on its stock value under current market conditions.
- Strategic Significance: Despite challenges posed by macroeconomic volatility and new U.S. tariffs, MKDWELL remains focused on leveraging AIOT technology to enhance consumer lives, demonstrating the company's commitment to growth in uncertain environments.
- Company Background: Founded in 2006, MKDWELL Tech Inc. specializes in developing automotive electronics and smart home products, showcasing its ongoing efforts in technological innovation and market adaptability.
